article thumbnail

STAT+: Pharmalittle: Woodcock to retire from the FDA; Acrotech urged to speed up confirmatory study of cancer drugs

STAT

They were approved under the FDA accelerated pathway in 2009 and 2014, respectively, for treating a rare form of blood cancer. The  The company’s final study plan was submitted to the FDA in 2022 and is expected to be completed  by 2030 , according to FDA briefing documents published earlier this week.

FDA 100
article thumbnail

Harnessing continuous improvement in the CAPA process

European Pharmaceutical Review

Rather than focusing on documentation with the aim to achieve compliance, the initial proposed framework shined a light on problem-solving and therefore the initiation of preventative action as a key part of the process. QMS market to value nearly $4b by 2030 Improving the CAPA process – what does the risk-based framework include?

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

A Final LDT Rule in April!? Will FDA be prepared?

The FDA Law Blog

Mullen — With comments due on the proposed LDT rule last week, FDA wasted no time updating the Unified Agenda to indicate that a final rule may be published in April ( here ). Under the Administrative Procedure Act, FDA is obligated to address major substantive issues when – and not so much if – it publishes a final rule.

FDA 69
article thumbnail

Top 20 Diagnostics Companies Based on 2022 Total Revenue

PharmaShots

In Sep 2022, Konica’s Chiropractic Straight Arm (CSA) system received the US FDA’s approval as an X-ray technology allowing diagnosis through visualization of the anatomy. In Jul 2022, DiaSorin’s Liaison MeMed BV test received the US FDA’s approval for its commercial launch across the US.

FDA 56
article thumbnail

Considerations for a Decentralized Manufacturing Paradigm

ISPE

Worldwide Modular Facilities in Pharmaceutical and Biotechnology Industry to 2030 - Impact Analysis of COVID-19.” www.prnewswire.com/news-releases/worldwide-modular-facilities-in-pharmaceutical-and-biotechnology-industry-to-2030 impact-analysis-of-covid-19-301332565.html AAPS PharmSciTech 23, no. 6 (2022):215. 39 PR Newswire.